Tartabull-Poutriel K, Toledo-Cabarcos Y, Nicolau-Pestana E

Language: Spanish
References: 12
Page: 264-2698
PDF size: 360.49 Kb.

ABSTRACT

Background: pseudomembranous colitis is a disease caused by Clostridium difficile in recent times has attracted the attention of the medical community, due to an increase in the incidence in health institutions, as well as in the community, motivated by the more frequent use and sometimes not ordered antimicrobials.
Objective: to describe a case of a patient with a postmortem diagnosis of pseudomembranous colitis.
Clinical case: a 71-year-old male patient with a history of chronic obstructive pulmonary disease and mitral prosthetic valve to receive from several months prophylactic antimicrobial cycles every month to avoid respiratory infections, who is admitted due to scarce diarrheic stools, but frequent with abundant blood and mucus accompanied by fever and abdominal pain, with an intra-hospital torpid evolution until his death, performing the diagnosis of pseudomembranous colitis in the necropsy study.
Conclusions: the pseudomembranous colitis produced by Clostridium difficile is a disease that has to be kept in mind in the diagnoses of hospitalized patients who are under antimicrobial treatment or who come from the community where they were prescribed with this type of drugs.

REFERENCES

1. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile Infection. Nat Rev Dis Primers. 2016; 2:16020. [ Links ]

2. Lital Meyer S, Ricardo Espinoza A, Rodrigo Quera P. Infección por Clostridium difficile: epidemiología, diagnóstico y estrategias terapéuticas. Rev Med Clin Condes. 2014;25(3):473-84. [ Links ]

3. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiologyof community associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med [Internet]. 2013 [citado 05 Mar 2019];173(14):[aprox. 9 p.]. Disponible en: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2013.7056 [ Links ]

4. Penichea AG, Savidgeb TC, Dann SM. Recent insights into Clostridium difficile pathogenesis. Curr Opin Infect Dis. 2013;26(5):447-453. [ Links ]

5. Leffler D, Lamont JT. Clostridium difficile Infection. N Engl J Med. 2015;372:1539-1548. [ Links ]

6. Dupont HL. Diagnosis and management of Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1216-23. [ Links ]

7. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH et al. Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections. Am J Gastroenterol [Internet]. 2013 [citado 05 Mar 2019];108(4):[aprox. 20 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23439232 [ Links ]

8. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect [Internet]. 2014 [citado 05 Mar 2019];20(Suppl 2):[aprox. 26 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24118601 [ Links ]

9. Martínez Rodríguez AA, Estrada Hernández LO, Tomé Sandoval P, Salazar Salinas J. Diarrhea due to Clostridium difficile inhospitalized patients. Med Int Méx. 2018;34(1):9-18. [ Links ]

10. Longo D. Clostridium difficile infection. Review article. N Engl J Med 2015;372(16):1539-48. [ Links ]

11. Furuya Kanamori L, Stone JC, Clark J. Comorbidities, exposure to medications, and the risk of communityacquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015 Feb;36(2):132-41. [ Links ]

12. Kyne K, Warny M, Qamar A. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody againsttoxin A. N Engl J Med. 2000;342(6):390-02. [ Links ]